NOVT — Novanta Inc.

Summary of Novanta Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue reached a record $248 million, exceeding guidance, with reported growth of 1% and organic revenue declines of 4%.
• Adjusted Gross Margin: Improved to 46.5%, up from 46.2% year-over-year.
• Adjusted EBITDA: $58 million, representing a 23% margin, up 2% year-over-year and 11% sequentially.
• Adjusted EPS: Increased to $0.87, up 2% year-over-year and 14% sequentially.
• Bookings: Grew 17% year-over-year and 4% sequentially, with a book-to-bill ratio of 1.03.
• Cash Flow: Operating cash flows were $8 million, below expectations due to temporary factors, including tax payments and increased inventory purchases.

2. Strategic Updates and Business Highlights

• Growth Platforms: Focus on AI-driven robotics, advanced surgery, digital manufacturing, and precision medicine. Medical markets now account for 53% of revenue.
• New Product Revenue: Grew nearly 60% year-over-year, with a strong pipeline of 20 new product launches in 2025.
• Design Wins: Increased by 50% year-to-date, indicating strong customer adoption and innovation momentum.
• Regional Manufacturing: Transitioning to a regionalized manufacturing model to enhance resilience and reduce costs related to tariffs.

3. Forward Guidance and Outlook

• Q4 2025 Revenue Guidance: Expected to be between $253 million and $257 million, indicating 3% organic growth and 6-8% reported growth year-over-year.
• Full Year 2025 Revenue: Expected to be approximately $975 million to $979 million, indicating flat organic growth.
• 2026 Outlook: Anticipating mid-single-digit organic growth, driven by momentum in Advanced Surgery and Robotics & Automation, while Precision Manufacturing is expected to recover gradually.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: Despite overall revenue growth, organic revenue declined by 4%, raising concerns about underlying demand.
• Precision Medicine Volatility: The Precision Medicine segment is experiencing challenges, leading to cautious guidance for 2026.
• Cash Flow Issues: Operating cash flows were significantly lower than expected, attributed to tax payments and restructuring costs.
• Tariff Impact: While mitigated, the previous tariff costs had an impact on margins, and the company is still navigating trade policy dynamics.

5. Notable Q&A Insights

• Robotics Contracts: The company is optimistic about a major design win in warehouse automation, with deployment expected to start in 2026.
• Humanoid Robotics: The potential market for humanoid robotics is still in early stages, with significant design win activity but limited current revenue.
• Regional Manufacturing Transition: Expected to be completed by the end of Q1 2026, with an anticipated margin uplift of around 100 basis points.
• Precision Medicine: The segment is not expected to grow in 2026, with resources being redeployed to higher growth areas.
• Warehouse Automation Revenue: Revenue from the $50 million opportunity in warehouse automation is expected to ramp up in 2026.

This earnings call reflects Novanta's strong performance in Q3 2025, with a focus on innovation and strategic growth, while also highlighting challenges in organic growth and specific market segments. The company remains optimistic about its future trajectory, particularly in medical technologies and robotics.